Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

160929 umc presentarion molecule to business

224 views

Published on

Radboudumc as business partner. Presentation by Dirkjan Masman (Director Valorisation) during 'From Molecule to Business' event by SMB Life Sciences and Health Valley at NovioTechCampus, Nijmegen, The Netherlands on September 29, 2016.

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

160929 umc presentarion molecule to business

  1. 1. SMB, Nijmegen 29 september 2016 Radboudumc als businesspartner
  2. 2. Dirkjan Masman From public to private to technology transfer 2013 Valorization Radboudumc 2011 Radboud Translational Research BV (Cyclotron on Radboud Campus) 2007 Business Generator Groningen (RUG & UMC Groningen) 2005 Angteq BV (UMC Groningen) 2003 Aesculaap BV (Utrecht University) 1996 Leadd BV (Leiden University) 1991 Institute for Veterinarian Research BV (Wageningen University) 1988 Groningen University, Postdoc 1986 University of Washington, Seattle, USA, Research fellow 1982 Groningen University, PhD
  3. 3. To take home • Medisch onderzoek is gericht op “unmet medical needs” • Innovaties komen bij patiënt via commercialisatie • Publiek-Private Consortia zijn onontbeerlijk • Radboudumc is “dus” ook een zakenpartner
  4. 4. Radboud Campus Nijmegen Radboud Campus Nijmegen Total employees: 5.050 Academic staff: 2.914 Annual turnover: € 542 million Students: 18.891 Scientific publications: 6.716 PhD Theses: 384 Total employees: 11.000 Annual turnover: € 1 billion Beds: 1000 Medical specialists: 587 Students: 3.300 Professors: 147 Scientific publications: 3.396 PhD theses: 186
  5. 5. Patient Radboud Personalized Healthcare A significant impact on healthcare Molecule Population 5
  6. 6. Research themes and institutes 6www.radboudumc.nl/Research/Themes/Pages/default.aspx NWO 10 juni 2016: Spinozapremie voor onderzoek naar afweersysteem
  7. 7. Valorisation Department (20 fte) • Business Development Spin-offs, licenses, patents • Legal Affairs MTA, NDA, CTA • Subsidies & Finance Horizon2020, ERC, NWO, EFRO • (Project) Support • Direct report to Board of Directors • Strong support Holding Company
  8. 8. Professionals Publications Shareholder License Contract Research Joint Research Impact of Radboudumc
  9. 9. TRL1 TRL2 TRL3 TRL4 TRL5 TRL6 TRL7 TRL8 TRL9 IMPACT Investeringsrisico Impactonhealthcare Radboudumc beleid ‘van idee tot spin-off’
  10. 10. TRL1 TRL2 TRL3 TRL4 TRL5 TRL6 TRL7 TRL8 TRL9 IMPACT Investeringsrisico Impactonhealthcare CHECK door Octrooifonds • Onderzoek financiering • 1e, 2e & 3e geldstroom Radboud Innovatie Fonds SUPPORT door Subsidies, non-diluting cash Radboudumc beleid ‘van idee tot spin-off’
  11. 11. TRL1 TRL2 TRL3 TRL4 TRL5 TRL6 TRL7 TRL8 TRL9 IMPACT Investeringsrisico Impactonhealthcare CHECK door Seed Late stage VC’s & banks Thuja Capital & PPM oost Octrooifonds • Onderzoek financiering • 1e, 2e & 3e geldstroom Radboud Innovatie Fonds SUPPORT door Subsidies, non-diluting cash Radboudumc Holding B.V. Pre-Seed Radboudumc beleid ‘van idee tot spin-off’
  12. 12. TRL1 TRL2 TRL3 TRL4 TRL5 TRL6 TRL7 TRL8 TRL9 IMPACT Investeringsrisico Impactonhealthcare CHECK door Seed Late stage VC’s & banks Thuja Capital & PPM oost Octrooifonds • Onderzoek financiering • 1e, 2e & 3e geldstroom Radboud Innovatie Fonds SUPPORT door Subsidies, non-diluting cash Radboudumc Holding B.V. Pre-Seed Radboudumc beleid ‘van idee tot spin-off’
  13. 13. LS&H portfolio Radboud Holding BV Year Spin-off’s founded 1996 1 2006 1 2007 1 2008 1 2009 1 2011 2 2012 3 2013 1 2014 4 2015 4 • Holding founded in 2007 • 19 companies (founded and aquired) • 153 fte • € 44 million invested
  14. 14. Founded 11-11-2014 Product: MedValue helps medical technology companies to extend their market opportunities, reduce the(financial) risks and to improve their impact and profit. MedValue provides options (report) to optimize the added value of innovations for patients and other stakeholders. Via Medvalue 4 “state of the art” Radboudumc operation rooms will be prepared, fully equipped with intra-operative imaging (CT, MRI, Echography), in vivo microscopy, intra-operative radiotherapy en intra-operative navigation. These facilities are also accessible for companies for testing, trials en training sessions. CEO: Richard van den Broek Headcount: 7 www.medvalue.nl
  15. 15. CEO: Juliëtte van den Dolder Headcount: 1 Stem cell researchers need 3D scaffolds to mimic human nature. Batch variation, animal origin, cell recovery are drawbacks of current 3D scaffolds. Noviocell´s technology is poly isocyanopeptide (PIC) hydrogel. PIC hydrogel is: • reproducible • synthetic • ease of cell recovery • performs uniquely like collagen • allows for modularity and tailoring of scaffold properties Noviocell develops a 3D solution for stem cell researchers 3D human organs2D cell culture ware Tubular structures of Huvec cells in PIC hydrogel with RGD peptide, VEGF and FGF PIC hydrogel performs uniquely like collagen Founded 12-11-2015
  16. 16. Binnenkort Meniscus prothese Multimodal imaging New Statines
  17. 17. To take home • Medisch onderzoek is gericht op “unmet medical needs” • Innovaties komen bij patiënt via commercialisatie • Publiek-Private Consortia zijn onontbeerlijk • Radboudumc is “dus” ook een zakenpartner
  18. 18. Dirkjan Masman (PhD) Director Knowledge and Technology Transfer Office Radboud University Medical Center Reinier Postlaan 2, HP903 6525 GC Nijmegen The Netherlands Dirkjan.masman@radboudumc.nl Office +31(0)24 3651500 Mob.+31 (0)6 222 473 56
  19. 19. Founded in 2006 Exit September 2015, still on Campus Product: a molecular diagnostic research and service company providing an expert- based, integrated approach in developing advanced and clinically useful molecular diagnostic assays for the uro-oncological practice. MDx Health CEO: J. Groen, PhD COO: Chr. Thibodeau Advisors Dr. Willem Melchers and Prof. Dr. Jack Schalken, RUMC
  20. 20. Legal entity founded: March 2007 Operational start: November 2012 Products: Pre-clinical and clinical drug candidates for mitochondrial disease www.khondrion.com CEO: Prof. dr. Jan Smeitink Headcount: 12 www.khondrion.com
  21. 21. Founded 18-8-2011 Product: RTM b.v. has been established with the objective of creating a fully equipped cyclotron facility. In this facility we aim to manufacture a range of GMP compliant, routine and experimental radiopharmaceuticals for our internal customers (research institutes of the Radboudumc) as well as for external clients. CEO: Frans Pieters Headcount: 10 www.radboudtranslationalmedicine.nl
  22. 22. Founded 2-8-2012 Activity: discovery and development of drugs against malaria. CEO: dr. Koen Dechering Headcount: 8 www.tropIQ.nl
  23. 23. Founded 8-10-2012 Product: Development, production and sales of medical devices and instruments - specifically in the field of Magnetic Resonance Imaging (MRI) and MR-guided interventions. CEO: Jan Sabisch CTO: Gerrit Tigelaar Headcount: 3 www.soteria-medical.com
  24. 24. Founded 9-10-2013 Product: life-prolonging therapeutics for advanced prostate cancer. A central process for an incipient cancer cell to become invasive is epithelial-to- mesenchymal transition (EMT). Oncodrone’s proprietary drug candidate (OCD155) reverses the EMT, thereby destroying the cancer. CEO: Henk Viëtor CSO: Jack Schalken Headcount: 4 www.oncodrone.com
  25. 25. Founded 28-2-2014 Product: Development of computer algorithms for analyzing medical imaging data. Thirona current focus is on quantitative computed tomography analysis for obstructive lung diseases. www.thirona.com CEO: Eva van Rikxoort CSO: Bram van Ginneken Headcount: 13 www.thirona.eu
  26. 26. Founded 8-5-2014 Product: ScreenPoint Medical develops image analysis technology for automated reading of mammograms and digital breast tomosynthesis. Initially, ScreenPoint will develop and market a next generation system for computer aided detection in screening mammography. CEO: Nico Karssemeijer, Michael Brady Headcount: 2 www.screenpoint-medical.com

×